ARCA biopharma, Inc.
|Number of Estimates|
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
Market Cap: 13.5 Million
Primary Exchange: NASDAQ
Shares Outstanding: 1.94 Million
Float: 1.93 Million
Sector: Health Technology
Longest drawdown: 2034 trading days
From: 2013-01-31 To: 2020-07-13
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|